3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Neuroendocrine Tumors
6
Carcinoid Tumor
5
Neoplasms
4
Carcinoma
3
Vipoma
2
Neoplasm Metastasis
2
Intestinal Obstruction
2
Carcinoma, Islet Cell
2
Somatostatinoma
1
Recurrence
1
Prostatic Neoplasms
1
Primary Inoperable Thymoma
1
Pleural Effusion
1
Peritoneal Neoplasms
1
Malignant Carcinoid Syndrome
1
Lymphangiomyoma
1
Lymphangioleiomyomatosis
1
Insulinoma
1
Glucagonoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Gastrinoma
1
Diarrhea
1
Chylous Ascites
1
Chylothorax
1
Carcinoma, Neuroendocrine
1
Breast Neoplasms
1
Ascites
1
Adenoma, Islet Cell
1
Interventions
Gemcitabine
13
Cisplatin
8
Capecitabine
8
Fluorouracil
5
pembrolizumab
4
Oxaliplatin
4
Sorafenib
3
Leucovorin
3
Erlotinib Hydrochloride
3
trametinib
2
regorafenib
2
durvalumab
2
N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine
2
Magnetic Resonance Spectroscopy
2
Lapatinib
2
trifluridine tipiracil drug combination
1
tremelimumab
1
spartalizumab
1
seribantumab
1
olutasidenib
1
olaparib
1
devimistat
1
derazantinib
1
dehydroftorafur
1
cediranib
1
cabozantinib
1
Trifluridine
1
Trastuzumab
1
Therapeutics
1
Sutures
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Bile Duct Neoplasms
×
Octreotide
×
Clear all
No trials found.